MARKET

LNTH

LNTH

Lantheus Hldg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.01
-0.11
-0.52%
Closed 17:37 05/17 EDT
OPEN
20.92
PREV CLOSE
21.12
HIGH
21.15
LOW
20.43
VOLUME
339.28K
TURNOVER
--
52 WEEK HIGH
24.26
52 WEEK LOW
10.52
MARKET CAP
1.42B
P/E (TTM)
-119.3072
1D
5D
1M
3M
1Y
5Y
--Credit Suisse Lifts Lantheus Holdings' PT to $20 From $17 on Revenue Outlook, Expected Progenics Pharmaceuticals Contribution; Neutral Rating Kept
MT Newswires · 05/05 10:41
8-K: Lantheus Holdings, Inc.
(EDGAR Online via COMTEX) -- FALSE000152103600015210362021-05-042021-05-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/05 08:27
Lantheus Holdings (LNTH) Beats Q1 Earnings and Revenue Estimates
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 600.00% and 5.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 13:20
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3)
Benzinga · 05/04 12:10
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, toda...
Business Wire · 05/04 12:00
10-Q: LANTHEUS HOLDINGS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Cautionary Note Regarding...
Edgar Online - (EDG = 10Q, 10K) · 05/04 11:46
Lantheus Holdings: Q1 Earnings Insights
  Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share fell 86.11% over the past year to $0.05, which beat the estimate of ($0.01).
Benzinga · 05/04 11:26
BRIEF-Lantheus Holdings Reports Q1 Adjusted EPS $0.05
reuters.com · 05/04 11:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LNTH. Analyze the recent business situations of Lantheus Hldg through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LNTH stock price target is 25.75 with a high estimate of 31.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 310
Institutional Holdings: 68.60M
% Owned: 101.65%
Shares Outstanding: 67.49M
TypeInstitutionsShares
Increased
35
3.53M
New
18
2.92M
Decreased
48
2.01M
Sold Out
20
611.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.54%
Healthcare Equipment & Supplies
-0.70%
Key Executives
Non-Executive Chairman/Independent Director
Brian Markison
President/Chief Executive Officer/Director
Mary Heino
Chief Financial Officer/Treasurer
Robert Marshall
Chief Operating Officer
John Bolla
Senior Vice President/General Counsel
Michael Duffy
Senior Vice President/General Counsel
Daniel Niedzwiecki
Senior Vice President
Etienne Montagut
Senior Vice President
Carol Walker
Vice President
Linda Lennox
Other
Paul Blanchfield
Other
Istvan Molnar
Independent Director
Gerard Ber
Independent Director
Samuel Leno
Independent Director
Heinz Mausli
Independent Director
Heinz Maeusli
Independent Director
Julie McHugh
Independent Director
Gary Pruden
Independent Director
James Thrall
No Data
  • All
  • Financials
  • Insiders
More
About LNTH
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.

Webull offers kinds of Lantheus Holdings Inc stock information, including NASDAQ:LNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LNTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LNTH stock methods without spending real money on the virtual paper trading platform.